REDUCE Deepak Nitrite

Phenolics contribution peaks in medium term; downgrade to REDUCE

Specialty Chemicals > Result Update > August 8, 2024

We downgrade Deepak Nitrate (DN) to REDUCE from Add, as it has run up ahead of earnings; we raise our SoTP-based TP to Rs2,900/sh (implying 35x PER on Jun-26E). DN's Q1FY25 EBITDA at Rs3.1bn (+47% YoY/+3% QoQ) was in line with our estimate. Revenue grew 23% YoY (flat QoQ) on volume growth from the standalone business, while DN's consol. quarterly EBITDA has stayed stable at ~Rs3bn over the last 4 quarters. We believe the phenolics segment has reached maximum volume potential (excluding downstream) from the current plant, while the standalone business will see some volume growth in H2. We cut FY25E/26E EPS by 6%/8%, to factor-in the lower margins in the standalone business. We increase the phenolics business EV/EBITDA to 15x from 12x, on incremental contribution from the new downstream products going forward.

Deepak Nitrite: Financial Snapshot (Consolidated)						
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E	
Revenue	79,721	76,818	88,705	100,211	112,638	
EBITDA	12,894	11,233	12,570	16,251	19,274	
Adj. PAT	8,520	7,311	8,473	10,931	12,019	
Adj. EPS (Rs)	62.5	54.8	62.1	80.1	88.1	
EBITDA margin (%)	16.2	14.6	14.2	16.2	17.1	
EBITDA growth (%)	(19.6)	(12.9)	11.9	29.3	18.6	
Adj. EPS growth (%)	(20.1)	(12.3)	13.4	29.0	10.0	
RoE (%)	22.9	16.5	16.4	18.2	17.1	
RoIC (%)	24.3	18.3	18.1	18.4	15.8	
P/E (x)	48.9	57.0	49.2	38.1	34.7	
EV/EBITDA (x)	32.1	36.8	33.2	26.1	22.6	
P/B (x)	10.2	8.7	7.5	6.4	5.5	
FCFF yield (%)	0.8	(0.3)	(0.9)	(1.3)	(2.5)	

Source: Company, Emkay Research

Standalone business witnesses volume uptick; phenol volumes nearing peak

The advanced intermediates (AI) segment saw improved domestic demand which led to volume uptick across select product categories, while realizations remained static. Debottlenecking activities were initiated, which lead to yield improvement in certain products. The Phenolics segment saw stable QoQ performance on the back of a favorable demand environment. We believe phenol-acetone capacities after debottlenecking are running at full capacity, thereby limiting volume growth for subsequent quarters. Agrochemicals demand remained soft in Q1, while contribution from other sectors such as dyes, pigments, paper, and homecare improved. The management anticipates revival of the agrochemical segment by H2FY25.

New projects under construction are on track; MIBK/MIBC project delayed

The management has guided for capex of Rs10-12bn in FY25, excl. any further growth capex during the tail-end of FY25. DN's backward integration to nitric acid will commence in early H2, while photo-chlorination and solvent projects, and progress of hydrogenation and nitration plants is on track. MIBK/MIBC project engineering is complete, and the civil work is near finalization. The company expects commissioning by Q4FY25, with substantial revenue flowing to FY26. Also, DN has announced setting-up a world scale acetophenone plant in coming 12 months (global demand: 60KT).

New capex in the phenolics business to drive growth beyond FY27

Deepak Chem Tech (DCTL) signed an MoU worth Rs90bn with the state government of Gujarat in Jan-24, taking the total value of MoUs signed to ~Rs140bn (previously signed an MoU worth Rs50bn in May-23 for MIBK, MIBC, Bisphenol-A, and Polycarbonate Compounding). The management is evaluating the overall project plan for PC compounding—from technology to EPC activities—before committing capex plans to shareholders. DN has funded Rs7.1bn to DCTL, making progress in its polycarbonate (PC) compounding facility. We believe current valuations have factored in the next leg of capex announcements and will make us constructive on the stock at lower levels.

TARGET PRICE (Rs): 2,900

Emkay

Target Price – 12M	Jun-25
Change in TP (%)	11.5
Current Reco.	REDUCE
Previous Reco.	ADD
Upside/(Downside) (%)	(5.1)
CMP (08-Aug-24) (Rs)	3,055.3
Stock Data	Ticker
52-week High (Rs)	3,169
52-week Low (Rs)	1,922
Shares outstanding (mn)	136.4
Market-cap (Rs bn)	417
Market-cap (USD mn)	4,963
Net-debt, FY25E (Rs mn)	649
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	1,290.0
ADTV-3M (USD mn)	15.4
Free float (%)	-
Nifty-50	24,117
INR/USD	84.0
Shareholding, Jun-24	
Promoters (%)	49.2
FPIs/MFs (%)	6.9/21.2

Price Performance						
(%)	1M	3M	12M			
Absolute	13.4	22.0	46.1			
Rel. to Nifty	14.4	12.8	18.5			

1-Year share price trend (Rs)



Meet Vora

meet.vora@emkayglobal.com +91 22 6624 2474

Meet Gada

meet.gada@emkayglobal.com +91 22 6612 1235

Exhibit 1: Result update

	Reported			Emkay	Emkay Est.		Full year			
P&L (Rs mn)	Q1FY24	Q4FY24	Q1FY25	YoY (%)	QoQ (%)	Q1FY25	vs. Est. (%)	FY24	FY23	YoY (%)
Net revenue	17,683	21,262	21,668	23	2	21,892	-1	76,818	79,721	-4
Material cost	(12,236)	(14,740)	(15,002)	23	2	(15,144)	-1	(52,361)	(53,476)	-2
Gross Profit	5,447	6,522	6,667	22	2	6,748	-1	24,457	26,245	-7
Gross margin (%)	30.8	30.7	30.8	-4 bps	9 bps	30.8	-6 bps	31.8	32.9	-109 bps
Employee cost	(842)	(929)	(953)	13	3	(963)	-1	(3,511)	(3,183)	10
Other overheads	(2,507)	(2,582)	(2,621)	5	2	(2,671)	-2	(9,769)	(10,169)	-4
Total expenses	(15,586)	(18,251)	(18,577)	19	2	(18,778)	(1)	(65,641)	(66,828)	-2
EBITDA	2,098	3,011	3,092	47	3	3,114	-1	11,178	12,893	-13
EBITDA margin (%)	11.9	14.2	14.3	240 bps	10 bps	14.2	4 bps	14.6	16.2	-163 bps
Other income	319	191	188	-41	-2	204	-8	816	476	71
Interest	(18)	(44)	(58)	218	30	(45)	27	(118)	(248)	-52
Depreciation	(381)	(465)	(475)	25	2	(439)	8	(1,657)	(1,663)	0
EO Items	-	798	-		(100)	-		798	-	
РВТ	2,017	3,492	2,748	36	-21	2,834	-3	11,017	11,458	-4
Тах	(518)	(953)	(723)	39	-24	(737)	(2)	(2,908)	(2,939)	-1
Adj. PAT	1,499	2,023	2,025	35	0	2,097	-3	7,593	8,519	-11
EO Items	-	516	-		(100)	-		516	-	
Reported PAT	1,499	2,538	2,025	35	-20	2,097	-3	8,108	8,519	-5
EPS (Rs)	11.0	18.6	14.8	35	-20	15.4	-3	59.4	62.5	-5
Costs as a % of sales										
Material cost	69.2	69.3	69.2	3 bps	-10 bps	69.2	5 bps	68.2	67.1	108 bps
Employee cost	4.8	4.4	4.4	-37 bps	3 bps	4.4	-1 bps	4.6	4.0	57 bps
Other overheads	14.2	12.1	12.1	-209 bps	-5 bps	12.2	-11 bps	12.7	12.8	-4 bps
Income tax rate	25.7	27.3	26.3	60 bps	-101 bps	26.0	29 bps	26.4	25.6	74 bps


Source: Company, Emkay Research

EBIT margin of the AI

business fell to a 10-


quarter low

Exhibit 2: AI business witnessing improved volumes at lower realizations



Source: Company, Emkay Research

Exhibit 3: The Phenolics business grew 37% YoY/was flat QoQ




The Phenolics segment maintained its volume, while pricing uptick in phenol was negated by falling acetone prices

Source: Company, Emkay Research


This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 08/11/2024 10:45 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 4: DCTL's revenue (phenolics) to rise, as it incurs most of the upcoming capex




Source: Company, Emkay Research

Exhibit 5: EBITDA CAGR expected at 24% over FY24-30E, along with margin expansion




Source: Company, Emkay Research





Source: Company, Emkay Research

Exhibit 7: Return ratios to largely remain healthy over the next few years



Source: Company, Emkay Research

This report is intended for team emkay @ whitemarquesolutions.com use and downloaded at 08/11/2024 10:45 A Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapor analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. re, this research report or research

Exhibit 8: We cut FY25/26E EPS by 6%/8%, to factor-in the lower margins in the standalone business

	FY25E			FY26E			
Particulars (Rs mn)	Revised	Earlier	Chg. (%)	Revised	Earlier	Chg. (%)	
Revenue	88,705	79,679	11	100,211	91,658	9	
EBITDA	12,570	13,327	-6	16,251	17,442	-7	
EBITDA margin (%)	14.2	16.7	-256 bps	16.2	19.0	-282 bps	
PAT	8,473	9,013	-6	10,931	11,832	-8	
EPS (Rs)	62	66	-6	80	87	-8	


Source: Emkay Research

Particulars (Rs mn)	FY26E	FY27E
DNL Standalone EBITDA	6,573	8,107
EV/EBITDA Target Multiple (x)	18	18
Target Enterprise Value (A)	118,315	145,918
DPL Discounted FY30E EBITDA	18,090	20,352
EV/EBITDA Target multiple (x)	15	15
Target Enterprise Value (B)	271,355	305,274
Total Enterprise Value (A+B)	389,670	451,192
Net Debt	6,832	19,192
Total Equity Value	382,837	432,000
No. of shares outstanding (mn)	136	136
Jun-26E Target Price (Rs/share)		2,900
CMP (Rs/share)		3,055
Upside		-5.1%


Source: Emkay Research



Exhibit 11: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research



This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 08/11/2024 10:45 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Deepak Nitrite: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	79,721	76,818	88,705	100,211	112,638
Revenue growth (%)	17.2	(3.6)	15.5	13.0	12.4
EBITDA	12,894	11,233	12,570	16,251	19,274
EBITDA growth (%)	(19.6)	(12.9)	11.9	29.3	18.6
Depreciation & Amortization	1,663	1,657	1,683	2,294	3,207
EBIT	11,231	9,576	10,887	13,958	16,067
EBIT growth (%)	(21.2)	(14.7)	13.7	28.2	15.1
Other operating income	0	0	0	0	0
Other income	476	761	799	839	881
Financial expense	248	118	174	414	1,134
РВТ	11,459	10,219	11,512	14,383	15,814
Extraordinary items	0	0	0	0	0
Taxes	2,939	2,908	3,039	3,452	3,795
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	8,520	7,470	8,473	10,931	12,019
PAT growth (%)	(20.1)	(12.3)	13.4	29.0	10.0
Adjusted PAT	8,520	7,311	8,473	10,931	12,019
Diluted EPS (Rs)	62.5	54.8	62.1	80.1	88.1
Diluted EPS growth (%)	(20.1)	(12.3)	13.4	29.0	10.0
DPS (Rs)	7.0	7.5	8.8	8.8	8.8
Dividend payout (%)	11.2	13.7	14.2	11.0	10.0
EBITDA margin (%)	16.2	14.6	14.2	16.2	17.1
EBIT margin (%)	14.1	12.5	12.3	13.9	14.3
Effective tax rate (%)	25.6	28.5	26.4	24.0	24.0
NOPLAT (pre-IndAS)	8,350	6,851	8,013	10,608	12,211
Shares outstanding (mn)	136.4	136.4	136.4	136.4	136.4

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	273	273	273	273	273
Reserves & Surplus	40,627	47,693	54,962	64,689	75,504
Net worth	40,900	47,966	55,235	64,962	75,777
Minority interests	0	0	0	0	0
Deferred tax liability (net)	1,565	1,715	1,715	1,715	1,715
Total debt	1,101	2,170	2,170	8,170	20,170
Total liabilities & equity	43,566	51,850	59,119	74,846	97,661
Net tangible fixed assets	18,895	22,223	31,275	44,981	65,774
Net intangible assets	522	704	704	704	704
Net ROU assets	0	0	0	0	0
Capital WIP	3,008	7,735	8,000	8,000	8,000
Goodwill	0	0	0	0	0
Investments [JV/Associates]	25	27	27	27	27
Cash & equivalents	4,168	5,846	1,521	1,337	978
Current assets (ex-cash)	24,669	24,405	27,897	31,278	34,929
Current Liab. & Prov.	7,720	8,830	10,044	11,220	12,490
NWC (ex-cash)	16,948	15,575	17,853	20,058	22,439
Total assets	43,566	52,111	59,380	75,107	97,922
Net debt	(3,067)	(3,677)	649	6,832	19,192
Capital employed	43,566	51,850	59,119	74,846	97,661
Invested capital	36,364	38,503	49,832	65,743	88,917
BVPS (Rs)	299.9	351.7	404.9	476.3	555.6
Net Debt/Equity (x)	(0.1)	(0.1)	0.0	0.1	0.3
Net Debt/EBITDA (x)	(0.2)	(0.3)	0.1	0.4	1.0
Interest coverage (x)	0.0	0.0	0.0	0.0	0.1
RoCE (%)	28.6	21.7	21.1	22.1	19.6

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	11,459	10,219	11,512	14,383	15,814
Others (non-cash items)	(246)	(627)	(799)	(839)	(881)
Taxes paid	(2,600)	(2,665)	(3,012)	(3,426)	(3,767)
Change in NWC	(3,945)	1,523	(2,278)	(2,205)	(2,381)
Operating cash flow	6,499	8,781	7,253	10,595	13,097
Capital expenditure	(3,231)	(9,894)	(11,000)	(16,000)	(24,000)
Acquisition of business	(3)	(2)	0	0	0
Interest & dividend income	476	761	799	839	881
Investing cash flow	(2,761)	(7,218)	(9,701)	(15,161)	(23,119)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(2,618)	1,068	0	6,000	12,000
Payment of lease liabilities	0	0	0	0	0
Interest paid	(248)	(118)	(174)	(414)	(1,134)
Dividend paid (incl tax)	(955)	(1,023)	(1,204)	(1,204)	(1,204)
Others	229	508	0	0	0
Financing cash flow	(3,591)	435	(1,378)	4,382	9,662
Net chg in Cash	148	1,998	(3,825)	(184)	(359)
OCF	6,499	8,781	7,253	10,595	13,097
Adj. OCF (w/o NWC chg.)	2,554	10,303	4,976	8,390	10,716
FCFF	3,268	(1,114)	(3,747)	(5,405)	(10,903)
FCFE	3,496	(471)	(3,121)	(4,980)	(11,155)
OCF/EBITDA (%)	50.4	78.2	57.7	65.2	68.0
FCFE/PAT (%)	41.0	(6.3)	(36.8)	(45.6)	(92.8)
FCFF/NOPLAT (%)	39.1	(16.3)	(46.8)	(51.0)	(89.3)

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	48.9	57.0	49.2	38.1	34.7
P/CE(x)	40.9	46.5	41.0	31.5	27.4
P/B (x)	10.2	8.7	7.5	6.4	5.5
EV/Sales (x)	5.2	5.4	4.7	4.2	3.9
EV/EBITDA (x)	32.1	36.8	33.2	26.1	22.6
EV/EBIT(x)	36.8	43.1	38.3	30.3	27.1
EV/IC (x)	11.4	10.7	8.4	6.4	4.9
FCFF yield (%)	0.8	(0.3)	(0.9)	(1.3)	(2.5)
FCFE yield (%)	0.8	(0.1)	(0.7)	(1.2)	(2.7)
Dividend yield (%)	0.2	0.2	0.3	0.3	0.3
DuPont-RoE split					
Net profit margin (%)	10.7	9.5	9.6	10.9	10.7
Total asset turnover (x)	1.9	1.6	1.6	1.5	1.3
Assets/Equity (x)	1.1	1.1	1.1	1.1	1.2
RoE (%)	22.9	16.5	16.4	18.2	17.1
DuPont-RoIC					
NOPLAT margin (%)	10.5	8.9	9.0	10.6	10.8
IC turnover (x)	2.3	2.1	2.0	1.7	1.5
RoIC (%)	24.3	18.3	18.1	18.4	15.8
Operating metrics					
Core NWC days	77.6	74.0	73.5	73.1	72.7
Total NWC days	77.6	74.0	73.5	73.1	72.7
Fixed asset turnover	3.0	2.6	2.4	2.0	1.6
Opex-to-revenue (%)	16.7	17.2	18.3	18.6	18.7

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 08/11/2024 10:45 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
14-Jul-24	2,775	2,600	Add	Meet Vora
07-Jun-24	2,282	2,600	Add	Meet Vora
22-May-24	2,464	2,600	Add	Meet Vora
07-Apr-24	2,220	2,600	Add	Meet Vora
26-Feb-24	2,284	2,600	Add	Meet Vora
15-Feb-24	2,283	2,600	Add	Meet Vora
18-Jan-24	2,293	2,600	Add	Meet Vora

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/11/2024 10:45 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of August 8, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGESL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of August 8, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the August 8, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 08/11/2024 10:45 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.